Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Gastroenterology. 2014;147(2):502–26.

Article  PubMed  Google Scholar 

Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829–34.

Article  CAS  PubMed  Google Scholar 

de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006;130(3):665–71.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. Genetic/familial high-risk assessment: colorectal (Version 2.2022): National Comprehensive Cancer Network; 2022 [updated December 7. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf

Mukherjee A, McGarrity TJ, Ruggiero F, Koltun W, McKenna K, Poritz L, et al. The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program. Hereditary cancer Clin Pract. 2010;8:9.

Article  Google Scholar 

Cross DS, Rahm AK, Kauffman TL, Webster J, Le AQ, Spencer Feigelson H, et al. Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Sci. 2013;15(12):933–40.

Google Scholar 

Singh H, Schiesser R, Anand G, Richardson PA, El-Serag HB. Underdiagnosis of Lynch syndrome involves more than family history criteria. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2010;8(6):523–9.

Article  Google Scholar 

Boland CR, Shike M. Report from the Jerusalem Workshop on Lynch Syndrome-Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology. 2010;138(7):2197. .e1-.e7.

Article  Google Scholar 

Evaluation of Genomic Applications in Practice Prevention Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Sci. 2009;11(1):35–41.

Google Scholar 

Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, et al. Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer. 2015;121(18):3281–9.

Article  PubMed  Google Scholar 

Hunter JE, Arnold KA, Cook JE, Zepp J, Gilmore MJ, Rope AF et al. Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam Cancer. 2017.

Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncology: Official J Am Soc Clin Oncol. 2013;31(20):2554–62.

Article  Google Scholar 

Heald B, Plesec T, Liu X, Pai R, Patil D, Moline J, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncology: Official J Am Soc Clin Oncol. 2013;31(10):1336–40.

Article  Google Scholar 

Cragun D, DeBate RD, Vadaparampil ST, Baldwin J, Hampel H, Pal T. Comparing Universal Lynch Syndrome Tumor Screening Programs to Evaluate associations between implementation strategies and patient follow-through. Genet Medicine: Official J Am Coll Med Genet. 2014;16(10):773–82.

Article  Google Scholar 

Kawakami H, Zaanan A, Sinicrope FA. MSI testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015;16(7):30.

Article  PubMed  PubMed Central  Google Scholar 

Chubak B, Heald B, Sharp RR. Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genet Sci. 2011;13(4):356–60.

CAS  Google Scholar 

Bombard Y, Rozmovits L, Sorvari A, Day C, Carroll JC, Kennedy E, et al. Universal tumor screening for Lynch syndrome: health-care providers’ perrspectives. Genet Sci. 2017;19(5):568–74.

Google Scholar 

Schneider JL, Davis J, Kauffman TL, Reiss JA, McGinley C, Arnold K, et al. Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genet Medicine: Official J Am Coll Med Genet. 2016;18(2):152–61.

Article  Google Scholar 

Cragun D, DeBate RD, Pal T. Applying Public Health Screening Criteria: how does Universal Newborn Screening compare to Universal Tumor Screening for Lynch Syndrome in adults with colorectal Cancer? J Genet Couns. 2015;24(3):409–20.

Article  PubMed  Google Scholar 

Subramonian A, Smith D, Dicks E, Dawson L, Borgaonkar M, Etchegary H. Universal tumor screening for Lynch syndrome: perspectives of patients regarding willingness and informed consent. Personalized Med. 2020;17(5):373–87.

Article  CAS  Google Scholar 

Ceballos RM, Newcomb PA, Beasley JM, Peterson S, Templeton A, Hunt JR. Colorectal cancer cases and relatives of cases indicate similar willingness to receive and disclose genetic information. Genet Test. 2008;12(3):415–20.

Article  PubMed  PubMed Central  Google Scholar 

Kim MH, Kim DW, Lee HS, Bang SK, Seo SH, Park KU, Oh HK, Kang SB. Universal Screening for Lynch Syndrome compared with pedigree-based screening: 10-Year experience in a Tertiary Hospital. Cancer Res Treat. 2023;55(1):179–88. https://doi.org/10.4143/crt.2021.1512. Epub 2022 Mar 21. PMID: 35313100; PMCID: PMC9873326.

Article  CAS  PubMed  Google Scholar 

Yamada A, Matsuoka Y, Minamiguchi S, Yamamoto Y, Kondo T, Sunami T, Horimatsu T, Kawada K, Seno H, Torishima M, Murakami H, Yamada T, Kosugi S, Sugano K, Muto M. Real-world outcome of universal screening for Lynch syndrome in Japanese patients with colorectal cancer highlights the importance of targeting patients with young-onset disease. Mol Clin Oncol. 2021;15(6):247. https://doi.org/10.3892/mco.2021.2409. Epub 2021 Oct 1. PMID: 34712484; PMCID: PMC8548998.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL, et al. Assessment of Tumor sequencing as a replacement for Lynch Syndrome Screening and current molecular tests for patients with Colorectal Cancer. JAMA Oncol. 2018;4(6):806–13.

Article  PubMed  Google Scholar 

Uson PLS Jr, Riegert-Johnson D, Boardman L, Kisiel J, Mountjoy L, Patel N, Lizaola-Mayo B, Borad MJ, Ahn D, Sonbol MB, Jones J, Leighton JA, Gurudu S, Singh H, Klint M, Kunze KL, Golafshar MA, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab TS. Jewel Samadder N. Germline Cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a Multicenter prospective study. Clin Gastroenterol Hepatol. 2022;20(3):e508–28. https://doi.org/10.1016/j.cgh.2021.04.013. Epub 2021 Apr 20. PMID: 33857637.

Article  CAS  PubMed  Google Scholar 

Hampel H, Yurgelun MB. Point/Counterpoint: is it time for Universal Germline Genetic Testing for all GI cancers? JCO. 2022;40:2681–92. https://doi.org/10.1200/JCO.21.02764.

Article  CAS  Google Scholar 

Yang Z, Gao J, Zheng J, Han J, Li A, Liu G, Sun Y, Zhang J, Chen G, Xu R, Zhang X, Liu Y, Bai Z, Deng W, He W, Yao H, Zhang Z. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduct Target Ther. 2024;9(1):56. https://doi.org/10.1038/s41392-024-01762-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamel D, Gray C, Walia JS, Kumar V. PARP inhibitor drugs in the treatment of breast, ovarian, prostate and pancreatic cancers: an update of clinical trials. Curr Drug Targets. 2018;19(1):21–37.

Article  CAS  PubMed  Google Scholar 

Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. 2016;27(5):795–800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, et al. Identification and confirmation of potentially actionable germline mutations in tumor-only genomic sequencing. JCO Precision Oncol. 2019;3. https://doi.org/10.1200/PO.19.00076.

Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014;147:401–5.

Article  CAS  PubMed  Google Scholar 

Abu-Ghazaleh N, Kaushik V, Gorelik A, Jenkins M, Macrae F. Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: systematic review and meta-analysis. Genet Medicine: Official J Am Coll Med Genet. 2022;24(5):971–85.

Article  CAS  Google Scholar 

Coughlin SE, Heald B, Clark DF, Nielsen SM, Hatchell KE, Esplin ED, et al. Multigene Panel Testing yields high rates of clinically actionable variants among patients with Colorectal Cancer. JCO Precis Oncol. 2022;6:e2200517.

Article  PubMed  PubMed Central  Google Scholar 

Uson PLS Jr., Riegert-Johnson D, Boardman L, Kisiel J, Mountjoy L, Patel N, et al. Germline Cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a Multicenter prospective study. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterological Association. 2022;20(3):e508–28.